Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Breast Cancer

Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials

Ann Oncol

Graeser M, Gluz O, Zu Eulenburg C, Kuemmel S, von Schumann R, Christgen M, Wuerstlein R, Pelz E, Heinrich Kreipe H, Schmid P, Thill M, Braun ML, Potenberg J, Schumacher C, Tio J, Schumacher J, Wujak L, Hartkopf AD, Just M, Schem C, Luedtke-Heckenkamp K, Hilpert F, Kentsch A, Kates RE, Nitz U, Harbeck N, West German Study Group investigators

doi: 10.1016/j.annonc.2025.07.016

Breast Cancer

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Int J Cancer

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D

doi: 10.1002/ijc.35432

Breast Cancer

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Int J Cancer

Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA

doi: 10.1002/ijc.70037

Breast Cancer

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer

J Clin Oncol

Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Pagan E, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Holtschmidt J, Gelber RD, Loibl S

doi: 10.1200/JCO-24-01360

Gastrointestinal Cancer

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis

Eur J Cancer

Leone AG, Petrelli F, Klempner SJ, Smyth EC, Sundar R, Lordick F, Lorenzen S, Masetti M, Obermannova R, Alsina M, Janjigian YY, Pietrantonio F

doi: 10.1016/j.ejca.2025.116155

Breast Cancer

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group

Lancet Oncol

Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlertsen B

doi: 10.1016/S1470-2045(25)00085-3

COMMENTED

Breast Cancer

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer

★ 0 Recommended and commented by Dr Andreas Müller, Faculty Member

Clin Breast Cancer

Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.clbc.2025.05.015

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

RECOMMENDED

Breast Cancer

Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

O'Brien KM, House MG, Goldberg M, Jones ME, Weinberg CR, de Gonzalez AB, Bertrand KA, Blot WJ, DeHart JC, Couch FJ, Garcia-Closas M, Giles GG, Kirsh VA, Kitahara CM, Koh WP, Park HL, Milne RL, Palmer JR, Patel AV, Rohan TE, Schoemaker MJ, Swerdlow AJ, Teras LR, Vachon C, Visvanathan K, Yuan JM, Zheng W, Nichols HB, Sandler DP

doi: 10.1016/S1470-2045(25)00211-6

Related content

Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group